Loading...
Phase I study of vemurafenib in children with recurrent or progressive BRAF(V600E) mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002)
Background: BRAF(V600E) mutation is present in a subset of pediatric brain tumors. Vemurafenib is an oral, selective ATP-competitive inhibitor of BRAF(V600E) kinase. The goal of this multi-center study conducted through the Pacific Pediatric Neuro-Oncology Consortium (PNOC) was to determine the reco...
Na minha lista:
| Udgivet i: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Impact Journals LLC
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7260122/ https://ncbi.nlm.nih.gov/pubmed/32523649 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27600 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|